Skip to content

Vitamin D Supplementation in Breastfeeding Women

Maternal Oral Vitamin D Supplementation Via Daily or Monthly Regimens and the Effect on Levels of Vitamin D in Human Milk and Infant Serum

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01240265
Enrollment
80
Registered
2010-11-15
Start date
2010-12-31
Completion date
2011-08-31
Last updated
2013-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infant Nutrition Disorders, Rickets, Vitamin D Deficiency

Keywords

Vitamin D deficiency, Rickets, Infant, Nutrition

Brief summary

Adequate vitamin D is essential for proper infant growth and development. However, human milk is low in vitamin D, and most infants do not receive recommended supplementation. Our aim is to assess the feasibility of providing adequate vitamin D to breastfed infants through maternal vitamin D supplementation. Forty non-pregnant, lactating women at least 18 years of age with exclusively breastfed infants between the ages of 1 and 6 months will be randomized to receive oral vitamin D as either 5,000 IU daily for 28 days or 150,000 IU as a single dose. Maternal serum calcium, phosphorus, vitamin D and 25(OH)D; maternal urinary calcium; maternal milk vitamin D and 25(OH)D will be measured on days 0, 1, 3, 7, 14, and 28 of the study; and infant serum vitamin D and 25(OH)D will be measured on days 0 and 28.

Interventions

DIETARY_SUPPLEMENTVitamin D3

150,000 IU orally given once

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Months to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Currently lactating mothers at least 18 years of age * Willing to continue exclusively breastfeeding their infant throughout the study interval * The infant is 1-6 months of age at the beginning of the study * Willing and able to participate in all aspects of the study * Mother and infant are in good health, as determined by the study investigator * Have been provided with, understand, and have signed the informed consent for themselves and their child.

Exclusion criteria

* Have recently travelled (within the preceding 30 days) or plan to travel south of 35 degrees north latitude during the study interval * Have recently or plan to engage in indoor tanning * Are currently taking medications that affect vitamin D metabolism, like steroids, anticonvulsants, or barbiturates * Are nursing multiple infants (e.g. twins) * Are taking greater than the daily recommended intake of 1000 mg elemental calcium as calcium supplements * Are taking greater than the standard daily dose of 400 IU of vitamin D found in prenatal vitamins * Infant weight below 1.67 kg * Mothers with baseline 25(OH)D levels \>70 ng/ml, and/or infants with baseline 25(OH)D levels \>70 ng/ml * History of kidney stones

Design outcomes

Primary

MeasureTime frameDescription
The number of days of detectable milk vitamin D concentrations28 daysTo compare the number of days of detectable milk vitamin D concentrations and incremental area under the curve between two dosing regimens of oral cholecalciferol in lactating mothers.

Secondary

MeasureTime frameDescription
Infant serum 25(OH)D concentration28 daysTo compare the change in serum 25(OH)D concentrations in infants receiving milk from mothers supplemented with either 5,000 IU daily or 150,000 IU monthly cholecalciferol

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026